相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
Frederique Berger et al.
BMJ OPEN (2022)
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
Komal L. Jhaveri et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).
Virginia G. Kaklamani et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
Thomas Meyskens et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study.
Belinda Kingston et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
Peter A. Fasching et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
Mafalda Oliveira et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
Aditya Bardia et al.
NATURE COMMUNICATIONS (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target
Madhusoodanan Mottamal et al.
ACS OMEGA (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2-advanced breast cancer: Phase 1 results.
Marina Maglakelidze et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC).
Komal L. Jhaveri et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER plus / human epidermal growth factor receptor 2-negative (HER-2) metastatic breast cancer (mBC).
Sarat Chandarlapaty et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER plus Breast Cancer
Jun Liang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
Malin Dahlgren et al.
JNCI CANCER SPECTRUM (2021)
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
Youssef El-Ahmad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
Kaitlyn J. Andreano et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
Elgene Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
James S. Scott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis
Adi Zundelevich et al.
BREAST CANCER RESEARCH (2020)
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using(18)F-FES PET/CT imaging
Agnes Jager et al.
BREAST CANCER RESEARCH (2020)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan et al.
CELL (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer
George S. Tria et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
Shanchun Guo et al.
Oncotarget (2018)
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells
Sean W. Fanning et al.
ELIFE (2018)
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
Yanan Kuang et al.
NPJ BREAST CANCER (2018)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)
Jiawang Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M. Spoerke et al.
NATURE COMMUNICATIONS (2016)
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
Sean W Fanning et al.
eLife (2016)
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models
Fiona Garner et al.
ANTI-CANCER DRUGS (2015)
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Michel van Kruchten et al.
CANCER DISCOVERY (2015)
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Angelo Di Leo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
Irene Kuter et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
John F. R. Robertson et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer
Peter McCormack et al.
CLINICAL BREAST CANCER (2008)
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Kendall W. Nettles et al.
NATURE CHEMICAL BIOLOGY (2008)
Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer
J. F. R. Robertson et al.
EUROPEAN JOURNAL OF CANCER (2007)
Structural basis for an unexpected mode of SERM-mediated ER antagonism
YL Wu et al.
MOLECULAR CELL (2005)
Double-blind, Randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial
CK Osborne et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Structural insights into the mode of action of a pure antiestrogen
ACW Pike et al.
STRUCTURE (2001)